Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

 
• By Ian Haydock, Anju Ghangurde, Jung Won Shin, and Joseph Haas

Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.

Osaka Castle in Osaka, Japan
Shionogi is headquartered in Osaka, Japan

More from Deals

More from Business